Less than two years after its IPO and months after shutting down its once-promising oncology program, Seattle-based Silverback Therapeutics will merge with another biotech company, San Diego-based ARS Pharmaceuticals. The… Read More
Silverback Therapeutics will lay off 27% of its workforce and close its oncology program, the Seattle company announced Thursday in its fourth quarter earnings report. The company reported disappointing clinical… Read More
When Juno Therapeutics launched in 2013, cell therapy was a nascent field. Early clinical studies were showing dramatic rates of remissions in leukemia patients treated with their own immune cells,… Read More
— Maren Costa, one of two former leaders of the Amazon Employees for Climate Justice group who was fired by Amazon last April, is now a principal lead designer at… Read More
In a year when large swaths of the economy sputtered due to the pandemic, Wall Street opened its doors to new entrants with 218 companies raising $78 billion through initial… Read More
— Expedia Group appointed Equifax President of Global Consumer Solutions Beverly Anderson as its newest board member. Prior to Equifax, Anderson was executive vice president of cards and retails services… Read More
Seattle biotech startup Silverback Therapeutics continues to raise capital to support development of its therapies for cancer, fibrosis, and other conditions. The company today announced a $85 million Series C round,… Read More
Silverback Therapeutics, a stealthy biotechnology startup, gave the first glimpse of its technology Wednesday as it announced an additional $37.5 million in funding, bringing its Series A round to a… Read More
Despite some knock-out successes and world-class research, Seattle’s biotechnology industry has remained relatively small compared to other hubs around the country. One of the biggest challenges for the region is… Read More
Last week we wrapped up a wild year for the Pacific Northwest’s top startups. Now it’s time to look ahead and see what’s on the horizon for the GeekWire 200, our… Read More
Eric Dobmeier, the longtime COO at public biotech company Seattle Genetics, is stepping down from his role to become CEO at stealthy biotech startup Silverback Therapeutics, GeekWire has learned. Dobmeier will… Read More
Silverback Therapeutics, a stealthy biotech startup co-founded by investor, entrepreneur and University of Washington neurosurgery professor Peter Thompson, has raised $10 million in venture funding, according to a filing with the… Read More